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Previous discussions have indicated that the small increases
of risk of venous thromboembolism (VTE) associated with
newer combined oral contraceptives (third generation,
containing desogestrel and gestodene) may be attributed
to bias due to cohort effects. In a case-control analysis, this
may produce an overestimate of risk of newer preparations.
In 10 centres in Germany and the UK, the Transnational
Study analysed data from 502 women aged 16–44 years
with VTE, and from 1864 controls matched for 5-year age
group and region. Information on lifetime exposure history
from all subjects was added to the dataset used in previous
analyses and entered into a Cox regression model with
time-dependent covariates. Based on 17 622 continuous
exposure episodes comprising 47 914 person-years of obser-
vation, the adjusted hazard ratio (equivalent to odds ratio,
OR) of VTE for the comparison of current users of
third-generation versus current users of second-generation
(primarily levonorgestrel compounds) combined oral con-
traceptives was 0.8 (0.5 to 1.3). The OR obtained in
standard case-control analysis had been 1.5 (1.1 to 2.1).
Adjustment for past exposures includes more information
and appears more valid than the standard cross-sectional
analysis. Using this approach, the Transnational Study data
show no evidence for an increased risk of VTE with
third- compared with second-generation combined oral
contraceptives.
Key words: case-control study/Cox regression analysis/epi-
demiology/oral contraceptive use/venous thromboembolism
Introduction
A good deal of the development of new oral contraceptives
(OC) was directed towards reducing the risk of thromboembolic
*For the Transnational Study on Oral Contraceptives and the Health
of Young Women — see appendix
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events which were found to be associated with OC use soon
after their introduction (Thorogood, 1993). It therefore came
as a surprise when studies published in 1995/1996 seemed to
show an increased risk of venous thromboembolism (VTE)
among users of newer OC compared with users of older OC
(Bloemenkamp et al., 1995; Farley et al., 1995; Jick et al.,
1995; Spitzer et al.; 1996; Farmer et al., 1997). This has
engendered considerable discussions on the safety of newer
(third-generation) OC in Europe which are still ongoing (Lewis
and Heinemann, 1997; Spitzer, 1997a,b; Vandenbroucke and
Rosendaal, 1997; Meirik, 1998). Because the differences found
between users of newer (third-generation products containing
,50 µg ethinyl oestradiol (EE2) and the progestins gestodene
and desogestrel) and older (second-generation, containing ,50
µg EE2 and primarily levonorgestrel) OC were small, ranging
between 1.3 and 2.2 (Table I), and because the population
impact of intervention is large, investigators were careful to
address and explore sources of potential bias and confounding
factors (Farley et al., 1995; Lewis et al., 1996b; Spitzer et al.,
1996; Spitzer, 1997b). The biases addressed included physician
diagnostic behaviour, preferential prescribing of newer OC to
risk groups, and a phenomenon known as depletion or attrition
of susceptibles, observed in a variety of epidemiological studies
(Miettinen and Caro, 1989; Moride and Abenhaim, 1994;
Posthuma et al., 1994).
Although the results of the Transnational Study (Spitzer
et al., 1996) were similar to others published at the same time,
the first analyses showed that adjustment for duration of use
of the current OC reduced the risk estimates for newer-
generation OC by about 12% (Spitzer et al., 1996). Additional
analyses showed that the magnitude of risk estimates for
individual progestins were closely linked with the time of
market introduction of the OC, with increasing risk estimates
of VTE found for newer OC (Lewis et al., 1996b). Because
it seemed unlikely that older, low-dose OC should consistently
show a more beneficial risk profile than newer OC, and because
it was found that a larger proportion of individuals using older
OC were long-term users than of those using newer OC, a
‘healthy user’ effect was postulated to be active within these
studies. This is a cohort effect based on the notion that long-
term users are individuals with good tolerance, whereas groups
with shorter duration of use may constitute a different risk set.
This results in a depletion of susceptibles in the group of older
exposures and loading of problem cases in the group of newer
exposures (Lewis et al., 1996b). Cross-sectional comparisons
of two groups using medications with different market entry
points are therefore likely to overestimate the risk associated
with the most recently introduced medication, especially when
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Table I. Summary of results of studies comparing risks of venous
thromboembolism among users of third-generation oral contraceptives with
users of second-generation oral contraceptives. Odds ratios (OR) with 95%
confidence intervals (95% C.I.)
Reference Investigation OR 95% C.I.
Farley et al. (1995) WHO study (UK; 2.2* (1.1 to 4.2)
hospital controls)
Farley et al. (1995) WHO study (UK; 1.4 (0.6 to 3.1)
community controls)
Jick et al. (1995) GPRD; case-control 2.1* (1.0 to 4.4)
Bloemenkamp et al. (1995) Leiden study 2.2 (0.9 to 5.4)
Spitzer et al. (1996) Transnational Study 1.5* (1.1 to 2.0)
Farmer et al. (1997) MediPlus Study 1.7* (1.0 to 2.8)
(age standardized)
Farmer et al. (1997) MediPlus Study 1.3 (0.7 to 2.4)
(age-matched)
*P , 0.05.
an adverse event is not expected to occur immediately after
exposure.
Standard case-control analysis considers current risk factors
and summary data on past exposures. The Cox proportional
hazards model with time-dependent covariates permits multiple
episodes of use and non-use of OC, including precise details
of duration and nature of each episode, to be used in adjustment
of the associations with current exposures. This approach
becomes possible through the availability of the lifetime
exposure history of all subjects included in our study. We
present here the results of the analysis of a Transnational
Study dataset, enhanced with information on all prior exposures
of the study subjects.
Materials and methods
Study design and conduct
The Transnational Study on oral contraceptives and the Health of
Young Women is a matched case-control study designed to assess
the risk of oral contraceptives on deep vein thrombosis and pulmonary
embolism (i.e. venous thromboembolism; VTE), arterial thrombotic
stroke and myocardial infarction. Its methods are almost identical to
those of the case-control study of the World Health Organization
Human Reproduction Unit, and have been detailed elsewhere (Spitzer
et al., 1993; Poulter et al., 1995; Lewis et al., 1996a). The cases
were women aged 16–44 years who had a diagnosis of VTE. Deep
vein thrombosis was defined by pain and tenderness in the extremities,
a precise record of knee circumference, and confirmation with imaging
procedures. The diagnosis of pulmonary embolism was based on
symptoms of pain in the chest or side, and confirmatory imaging
procedures. The cases were accrued in hospital between early 1993
(first case index date 2 January 1993) and 20 October 1995 in centres
in Germany and the UK. These were matched by centre and 5-year
age-band to at least one community and one hospital control.
A full exposure history was documented by filling in a calendar
sheet which identified exposure by month since menarche, indicating
the first eligibility to take OC. Exposure periods of interest were the
use of an OC and the brand of OC used, pregnancy, and periods of
non-exposure. Current use of OC was defined as the OC used within
a 3-month window at the time of the event (for a case), the hospital
admission (for a hospital control) or the date of interview (for a
community control). Prior use of OC was defined as any use that
ended before this period. For this analysis, first-generation OC were
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defined as any preparation that contained ù50 µg of EE2, regardless
of progestin content. Second-generation OC were defined as those
which had ø35 µg of EE2 and contained a progestin other than
gestodene or desogestrel. Preparations containing norgestimate were
included with the second-generation products to retain consistency
with other analyses. Third-generation OC were defined as combination
products with low doses of EE2 (usually 30 µg or 20 µg) and either
gestodene or desogestrel. Separate analyses for individual progestins
were conducted. OC classification lists are available from the authors
(Lewis et al., 1996a).
Data processing and analysis
All data were checked manually and by computer for eligibility and
correct matching. The clinical data were coded twice and difficult or
unreconciled diagnoses were arbitrated by local and international
panels of clinical specialists. All other data were entered twice and
verified. Plausibility checks of current and prior exposures were
conducted by numerous procedures, including verification of age,
periods of pregnancy, and presence of the indicated product on the
market. The data on exposure histories from the pill calendar sheet
were entered into a separate database and merged with the main
Transnational Study dataset. The data were first modelled for the
stroke component of the study. This dataset was chosen because it
contained adequate exposures of second- and third-generation OC for
cases and controls (Heinemann et al., 1997). This approach permitted
an unbiased configuration and exploration of this complex dataset.
The model derived from this work was then applied to the new
VTE dataset.
Figure 1 shows the configuration of the new dataset for analysis
using the pill calendar data. Ordinarily, cases and controls are captured
within a 3-year study period, and their exposures are assessed for the
time during which the event occurred. Standard analyses rarely
account for prior exposures, which are key for the attrition of
susceptibles. These prior exposures may constitute periods of chal-
lenge (high-risk periods). To adjust adequately for these periods, the
data were analysed using a Cox regression model on a fixed time
axis defined by the successive calendar months (Cox and Oakes,
1984; Clayton and Hills, 1993; Collet, 1994). This method is similar
to the Poisson regression, but based on much finer subdivisions in
time. In using this method, we computed the conditional probability
that, given a failure occurred in a set of subjects, it had occurred in
the case rather than in some other member of the risk set. The profile
log likelihood of a cohort corresponded with the conditional log
likelihood obtained for individually matched case-control studies
(Breslow and Day, 1980; D’Agostino et al., 1990). In our approach,
all study subjects were right-censored at the same time by virtue of
their being accrued almost simultaneously within a case-control
setting. The subject’s risks were determined by different exposure
periods and likelihood of exposure to various agents.
We defined a calendar axis from 0 to 458 months for the total
period of observation. We left-censored the individual members at 9
years of age, this being the age of first exposure to risk of the subject
with the earliest exposure to OC or pregnancy. The exposure episodes
j of each subject i were arrayed along this time axis by month (1,...,
k). Each subject was followed from cohort entry (t0i1) to case-control
study entry (tmiki) by month through various exposure periods (tmij,
where j 5 1,..., k). Event status is defined by the outcome variable
d, corresponding to case or control status. The time-dependent variable
entered into the model was the exposure or non-exposure to specific
OC at monthly intervals. We adjusted for non-time-dependent vari-
ables shown to influence risk, such as body mass index (BMI),
alcohol use, index age and smoking status, as well as for current and
previous duration of use by generation and for switching. The analyses
Past exposures and oral contraceptive risks
Figure 1. New information added in the Transnational Study ‘pill calendar’ for longitudinal analysis. In addition to current exposures (case-
control setting), past exposure histories and duration of oral contraceptive use were included in a Cox regression model with time-dependent
covariates (cohort setting). 1 5 first generation (gen); 2 5 second generation; 3 5 third generation; P 5 pregnancy, no use; open box 5 no
use.
were performed with STATA 5.0 (StataCorp, 1997). We calculated
adjusted hazard ratios expressed as odds ratios (OR; signifying their
origin from a case-control study) and their 95% confidence intervals
to estimate the risk of VTE associated with use of the various
categories of OC investigated.
Results
Data on 2366 women aged 16–44 (502 cases and 1864 controls)
were collected from 1 January 1993 to 20 October 1995 in
the UK and Germany. Cases differed from controls in that a
larger proportion of cases had a BMI .30 (17.7 versus 9.9%),
were current smokers (45.8 versus 39.3%), and were current
users of oral contraceptives (67.5 versus 41.8%) (see also
Spitzer et al., 1996). The stratification of current use and
previous use by age in Table II shows a predominance of
current users of third-generation OC in the age group 16–24
years among cases (41.4% versus 25.4% of controls). Use of
third-generation OC is equally distributed among previous
users (26.7% of cases and 30.3% of controls) in this age
group. Current use of second-generation OC predominates in
the age groups 25–44, whereas there is a distinct increase in
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the proportion of previous users of first-generation OC in the
older age groups. Current use of OC decreases considerably
with age in both cases and controls (Table II). The proportions
of previous use are similar for cases and controls in each
age group.
The average current duration of use of all OC increases
with age with pronounced age-related differences in length of
use by generation (Table III). The total exposure times decline
from first to third generation in all age groups for cases (mean
times: for first generation 78, second 52, third 30 months) and
controls (first generation 71, second 58, third 30 months). The
proportion of cases who have used OC for .60 months is
lowest in the group of third-generation OC users (12%)
compared with cases using second- (20.1%) and first- (48.7%)
generation OC. About 16% of cases and 22% of controls were
never users, and 41.2% of cases and 42.2% of controls stayed
on the same OC throughout. Defined switches from second-
to third-generation OC took place in 9.6% of cases and 6.2%
of controls. Multiple switches with no clear pattern were found
in 26.3% of cases and 23.4% of controls.
A total of 17 622 separate exposure episodes covering 47
M.A.Lewis et al.
Table II. Distribution of current and previous use of oral contraceptives by
10-year age groups and type of oral contraceptive in 502 cases and 1864
controls of the Transnational Study on Oral Contraceptives and the Health
of Young Women
Age 16–24 years Age 25–34 years Age 35–44 years
n % n % n %
Current use
Controls
No current use 217 41.7 388 54.3 480 76.2
First generation 11 2.1 21 2.9 27 4.3
Second generation 154 29.6 186 26.1 84 13.3
Third generation 132 25.4 102 14.3 25 4.0
Progestogen-only 6 1.2 17 2.4 14 2.2
Total 520 100.0 714 100.0 630 100.0
Cases
No current use 27 19.3 53 27.6 83 48.8
First generation 6 4.3 13 6.8 18 10.6
Second generation 46 32.9 68 35.4 32 18.8
Third generation 58 41.4 53 27.6 30 17.6
Progestogen-only 3 2.1 5 2.6 7 4.1
Total 140 100.0 192 100.0 170 100.0
Previous usea
Controls
No previous use 172 33.2 189 22.4 215 30.4
First generation 18 3.5 96 11.4 220 31.1
Second generation 171 33.0 418 49.6 249 35.2
Third generation 157 30.3 139 16.5 24 3.4
Total 518 100.0 842 100.0 708 100.0
Cases
No previous use 36 30.0 60 25.5 59 32.1
First generation 5 4.2 29 12.3 60 32.6
Second generation 47 39.2 110 46.8 54 29.3
Third generation 32 26.7 36 15.3 11 6.0
Total 120 100.0 235 100.0 184 100.0
aMultiple mentions possible.
914 woman-years of observation were included in the Cox
regression model with time-dependent covariates. The relative
risk (hazard ratio; OR) for the model which included adjust-
ments for exposure in each episode by generation, age, BMI,
smoking, alcohol use, duration of current use by generation
(first to third) and duration of previous use by generation (first
to third) as linear variables, and ‘switching’ by generation was
2.90 [95% confidence interval (C.I.): 2.06 to 4.09] for any OC
use versus non-use, and 8.48 (3.02 to 23.86) for use of first
generation versus non-use (Table IV). The OR for second
generation versus non-use was 2.85 (1.92 to 4.22) and for
third generation it was 2.26 (1.46 to 3.50), all statistically
significant. The direct comparison between users of third-
generation versus second-generation OC resulted in a risk
estimate of 0.79 (95% C.I. 0.50 to 1.26), which was not
statistically significant. Estimates comparing users of various
progestins with users of levonorgestrel-containing OC show
no significant differences (Table IV).
There were no differences in the risk estimates when we
stratified by 10-year age groups, nor was there a trend by time
of market introduction overall or for any age group. Although
there were absolute differences in risk estimates when compar-
ing users with non-users in the UK (2.2; 1.48 to 3.3) and
Germany (5.6; 2.9 to 0.8) due largely to the absence of current
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Table III. Duration of current and previous use (months) by age group
(years) and by oral contraceptive generation. Absolute numbers (n), average
durations (mean) and standard deviation (SD) from the mean
Cases (n 5 502) Controls (n 5 1864)
n Mean SD n Mean SD
Current use
Overall duration of use
Age 16–24 113 19.3 19.1 303 24.2 22.3
Age 25–34 139 37.5 37.5 326 37.6 35.3
Age 35–44 87 59.7 64.4 150 63.5 57.8
Duration of first-generation use
Age 16–24 6 14.5 15.0 11 26.9 30.9
Age 25–34 13 68.2 34.5 21 48.8 39.0
Age 35–44 18 106.2 87.7 27 108.1 71.9
Duration of second-generation use
Age 16–24 46 18.5 17.1 154 26.7 23.7
Age 25–34 68 38.8 37.5 186 42.6 36.9
Age 35–44 32 55.6 52.5 84 63.1 51.9
Duration of third-generation use
Age 16–24 58 20.4 20.8 132 21.5 19.9
Age 25–34 53 24.7 28.2 102 27.5 27.9
Age 35–44 30 38.7 47.2 25 28.7 28.0
Previous use
Overall duration of use
Age 16–24 79 26.5 22.1 292 30.2 25.1
Age 25–34 165 60.3 42.4 608 64.9 41.4
Age 35–44 144 83.7 61.7 538 88.5 63.6
Duration of first-generation use
Age 16–24 5 23.4 20.5 18 25.4 20.5
Age 25–34 29 46.8 44.7 96 47.9 41.1
Age 35–44 60 73.2 60.7 220 73.6 56.8
Duration of second-generation use
Age 16–24 47 22.4 18.6 171 25.4 21.9
Age 25–34 110 46.5 33.4 418 55.3 39.2
Age 35–44 54 56.3 49.8 249 62.1 50.0
Duration of third-generation use
Age 16–24 32 19.9 16.6 157 20.4 21.1
Age 25–34 36 21.6 23.1 139 31.2 26.1
Age 35–44 11 29.3 27.9 24 27.5 19.1
users of first-generation OC in the UK, there were no important
differences in the adjusted comparisons of users of third-
generation with users of second-generation OC between coun-
tries (UK: 0.85, 0.50 to 1.45; Germany: 0.76, 0.32 to 1.82).
No important differences were found either between hospital
and community controls when comparing current OC use
against no current use (hospital controls: 2.42, 1.74 to 3.38;
community controls: 2.19, 1.54 to 3.11), or when comparing
users of third- with users of second-generation OC (hospital
controls: 0.84, 0.52 to 1.35; community controls: 0.82, 0.51
to 1.33). The model was stable, in that results were altered
only slightly as additional adjustment variables were introduced
(unadjusted model: 0.84, 0.59 to 1.18; full adjustment: 0.79,
0.50 to 1.26). Concerning other variables which might poten-
tially have influenced the occurrence of VTE, the most pro-
nounced independent risk factors for VTE appeared to be a
BMI .30 (2.72, 1.80 to 4.11), current smoking (1.42, 1.12 to
1.79) and diabetes (2.41, 1.07 to 5.42). The use of alcohol
was associated with a decreased risk of VTE (0.50, 0.36 to
0.69, versus non-use of alcohol).
Past exposures and oral contraceptive risks
Table IV. Main results of Cox regression analysis with time-dependent
covariates on the risk of venous thromboembolism (VTE) in young women.
Hazard ratios expressed as odds ratios (OR); 95% confidence intervals (95%
CI) and P-values for the analysis of 502 cases and 1864 controls for
exposure in each episode by generation, adjusted for age, body mass index,
smoking, alcohol use, duration of current use by generation (1–3) and
duration of previous use by generation (1–3) as linear variables, ‘switching’
by generation. The comparisons of generations and progestins with each
other relate to users only (339 cases and 779 controls). In the last four
rows, progestins are arranged by sequence of market introduction.
Comparison OR 95% CI P
No current use of OC (reference 1.00 – –
group)
OC use vs. no current OC use 2.90 2.06 to 4.09 ,0.001
First generation vs. no OC use 8.48 3.02 to 23.86 ,0.001
Second generation vs. no OC use 2.85 1.92 to 4.22 ,0.001
Other second generation vs. no OC 3.25 1.89 to 5.58 ,0.001
Levonorgestrel vs. no OC 2.63 1.75 to 3.95 ,0.001
Norgestimate vs. no OC 3.65 2.17 to 6.12 ,0.001
Third generation vs. no OC use 2.26 1.46 to 3.50 ,0.001
Desogestrel 30 vs. no OC 2.52 1.56 to 4.09 0.005
Gestodene vs. no OC 2.25 1.40 to 3.60 0.001
Desogestrel 20 vs. no OC 1.56 0.85 to 2.86 0.150
Second generation (reference group) 1.00 – –
Third generation vs. second 0.79 0.50 to 1.26 0.323
generation
Levonorgestrel (LNG; reference 1.00 – –
group)
.50 µg EE2 vs. LNG 2.89 1.04 to 8.01 0.041
Other second generation vs. LNG 1.08 0.61 to 1.91 0.791
Desogestrel 30 vs. LNG 1.07 0.59 to 1.96 0.818
Gestodene vs. LNG 0.58 0.32 to 1.03 0.063
Norgestimate vs. LNG 1.02 0.50 to 2.05 0.965
Desogestrel 20 vs. LNG 0.71 0.31 to 1.62 0.415
EE2 5 ethinyl oestradiol; OC 5 oral contraceptive; vs. 5 versus.
Discussion
There are some indications that the studies on oral contracept-
ives do not meet one of the primary conditions of the case-
referent approach, in that the processes which bring the cases
to attention and by which controls are selected may not be
independent of the exposure (Miettinen and Caro, 1989). This
may lead to confounded or biased results when the traditional
cross-sectional methods of analysis are used (Lewis et al.,
1996b; Suissa et al., 1997). This is expressed by a variety of
inconsistent and implausible results which have led authors to
postulate distortion due to heterogeneous exposure groups. A
case-control study measures the instantaneous drop-out rate
when only individuals (and their controls) who have been
healthy up to the time of the index event are included. This
approach is best suited for well-defined events which occur
soon (preferably days or weeks) after a drug is taken. For an
ill-defined and non-specific event such as VTE, this approach
becomes problematic when the observed time window of
exposure becomes large. The problem is further compounded
if there have been previous exposure episodes which can be
regarded as high-risk or challenge periods for VTE. For OC,
exposure likelihoods additionally differ with age, in that older
individuals are more likely to have been exposed to previous
generation OC. Lastly, a comparison of older and newer
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generation OC becomes difficult because high-risk members
of the older user group may have dropped out due to events
or other intolerances and possibly switched to the apparently
more tolerable newer products (Lewis et al., 1996b). There is
no assurance that the cohort of exposed individuals used as
the index population is actually comparable to the cohort of
unexposed individuals used as the reference population. There
are good reasons indeed to believe that they are not comparable,
because the comparison groups for exposure are not homogen-
eous. In our study, these differences are reflected by differing
proportions of users of specific types of OC in the various age
groups (Table II), by differences in the lengths of current and
previous exposure episodes across age groups and generations
(Table III), and by differences in switching patterns between
cases and controls.
We adjust for these differences in an enhanced dataset which
now includes past exposures and precise duration terms along
a time axis. The model used is remarkably stable, and the
results appear consistent and plausible. The main effect of the
adjustment for prior exposure is a reduction of the risk estimate
for users of third-generation OC from 4.8 in the original
analysis to 2.3. The comparison of users of third- with users
of second-generation OC shows that there is no evidence for
an increased risk of third-generation OC (0.79, 0.50 to 1.26;
previous estimate 1.5, 1.1 to 2.2) (Lewis et al., 1996b; Spitzer
et al., 1996). The results indicate that the relevant effects of
prior exposure for the comparisons between OC user groups
are removed. This is demonstrated by the consistency of the
results when stratifying by control group and by country, and
by the absence of the dependence of risk estimates on the time
of market introduction of the various progestins as shown in
standard logistic regression (Lewis et al., 1996b).
A conventional case-control comparison cannot adequately
account for those individuals who have not successfully passed
their high-risk periods and who have become cases in the past.
The present approach also cannot deal with this issue, but it
does use the prior exposure data in as complete a manner as
possible. Any estimates achieved with this approach will
underestimate the risk in the users who have passed many
high-risk periods (i.e. older users of older generation OC)
compared with the risk in those who have not traversed as
many high-risk periods (i.e. younger users and users of newer
products). Recall bias can never be fully excluded in this form
of study. However, validity checks of pregnancies and OC
market introduction dates showed that women placed their OC
brand in the correct time-frame, so that recall bias is unlikely
to be an issue. A further limitation is that lifetime histories of
other variables, such as BMI and smoking, were not collected,
but only data on such variables at the time of entry of the
subjects into the case-control study. Their influence cannot be
estimated over time, but only in a cross-sectional fashion.
However, it should be noted that the unadjusted model yielded
virtually identical results, which argues against important
distortion by these factors. The full adjustment for past
exposures among these healthy women includes more informa-
tion and provides more precision than the standard cross-
sectional analysis.
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